Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2012
08/23/2012WO2012112447A2 Histone deacetylase inhibitors and methods of use thereof
08/23/2012WO2012112437A1 Filmcoated solid dosage forms comprising honey in the coating
08/23/2012WO2012112421A1 Water soluble nutritional compositions comprising cereal beta-glucan and resistant starch
08/23/2012WO2012112364A1 Lactam derivatives as dgat-1 inhibitors
08/23/2012WO2012112363A1 Cathepsin cysteine protease inhibitors
08/23/2012WO2012112355A1 Methods for controlling pain in equines using a transdermal solution of fentanyl
08/23/2012WO2012112349A1 Skin treatment in antiseptic thin film form with silver
08/23/2012WO2012112348A1 Methods for controlling pain in canines using a transdermal solution of fentanyl
08/23/2012WO2012112345A1 Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus
08/23/2012WO2012112340A2 Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
08/23/2012WO2012112232A1 METHODS AND COMPOSITIONS FOR TREATING β-THALASSEMIA AND SICKLE CELL DISEASE
08/23/2012WO2012112140A1 Extended release powder and aqueous suspension comprising methylphenidate
08/23/2012WO2012112048A1 Modulators of prr and gpcr signalling
08/23/2012WO2012111997A2 Cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory t-cells as active ingredient
08/23/2012WO2012111996A2 Transdermal delivery system containing galantamine or salts thereof
08/23/2012WO2012111995A1 Oxime derivatives as gpr119 agonists
08/23/2012WO2012111965A2 Orally administered sustained-release triple-layer pill containing tamsulosin or pharmaceutically acceptable salt thereof
08/23/2012WO2012111961A2 Orally administrated sustained-release tablet containing tianeptine or pharmaceutically acceptable salt thereof
08/23/2012WO2012111920A2 Pharmaceutical composition containing fenofibrate for prevention of sepsis
08/23/2012WO2012111795A1 Ameliorating agent for lifestyle-related diseases containing water extract of colored onion
08/23/2012WO2012111790A1 Potentiator of antitumor activity of chemotherapeutic agent
08/23/2012WO2012111627A1 Nanoparticle containing prostaglandin i2 derivative
08/23/2012WO2012111487A1 Compound having acceptor groups, and organic thin film and organic thin film element using same
08/23/2012WO2012111380A1 Auto-magnetic metal salen complex compound
08/23/2012WO2012111187A1 Skin collagen production promoter
08/23/2012WO2012111029A2 Ophthalmic composition for enabling dilation of pupils
08/23/2012WO2012111024A1 Pharmaceutical compositions of dexlansoprazole
08/23/2012WO2012111021A1 Substituted 1, 2, 3, 4-tetrahydroquinolin-7-yl carbamates as acetylcholinesterase inhibitors for treatment of alzheimer's disease
08/23/2012WO2012111020A1 Pyrrolo [2,1-c]1,4]naphthodiazepine linked piperazine compounds and a process for the preparation thereof
08/23/2012WO2012111017A1 3-arylethynyl substituted quinazolinone compounds
08/23/2012WO2012111016A1 2-anilino nicotinyl linked 2-amino benzothiazole conjugates and process for the preparation thereof
08/23/2012WO2012111011A2 Low dosage combinations of fluoxetine and reboxetine for treating obesity
08/23/2012WO2012110986A1 Novel pyrazole and imidazole derivatives useful as orexin antagonists
08/23/2012WO2012110959A1 2-phenyl benzothiazole linked imidazole compounds as potential anticancer agents and process for the preparation thereof
08/23/2012WO2012110953A1 Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
08/23/2012WO2012110946A1 Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate
08/23/2012WO2012110912A1 Sustained release composition of memantine
08/23/2012WO2012110911A1 Novel polymorphic form of teriflunomide
08/23/2012WO2012110860A1 TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
08/23/2012WO2012110840A1 Diaryl ether linked pyrrolo [2,1-c][1,4] benzodiazepine hybrids and process for the preparation thereof
08/23/2012WO2012110774A1 Selective fak inhibitors
08/23/2012WO2012110773A1 Fak inhibitors
08/23/2012WO2012110770A2 Pharmaceutical composition
08/23/2012WO2012110768A1 Therapeutic uses of diarylalkanes such as mitotane
08/23/2012WO2012110672A1 Pharmaceutical composition of acyclovir prodrugs for topical use
08/23/2012WO2012110631A1 Pharmaceutical formulation for topical administration comprising b220
08/23/2012WO2012110603A1 Novel sulfonaminoquinoline hepcidin antagonists
08/23/2012WO2012110599A1 Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
08/23/2012WO2012110537A1 Veterinary anti-prolactin composition for ruminants
08/23/2012WO2012110518A1 Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy
08/23/2012WO2012110470A1 Novel benzodioxole piperazine compounds
08/23/2012WO2012110463A1 Active substance for treating inflammatory disease conditions in the oral cavity
08/23/2012WO2012110462A1 Liquid propellant-free formulation comprising an antimuscarinic drug
08/23/2012WO2012110459A1 1,4-oxazepines as bace1 and/or bace2 inhibitors
08/23/2012WO2012110456A1 Absorbent dressings with painkilling activity
08/23/2012WO2012110441A1 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
08/23/2012WO2012110440A1 6 - cyclobutyl - 1, 5 - dihydro - pyrazolo [3, 4-d] pyrimidin- 4 - one derivatives their use as pde9a inhibitors
08/23/2012WO2012110425A1 Methods for monitoring the response to treatment and for treating colorectal cancer
08/23/2012WO2012110249A1 Haprolid and derivatives thereof as inhibitors of hcv
08/23/2012WO2012110222A1 Rapidly disintegrating oral film formulation for olanzapin
08/23/2012WO2012110190A1 Novel p2x7r antagonists and their use
08/23/2012WO2012110017A1 Dietetic or pharmaceutical preparation containing tartary buckwheat
08/23/2012WO2012110010A1 Pregnanolone derivatives substituted in 3alpha-position with the cationic group, method of their production, usage and pharmaceutical preparation involving them
08/23/2012WO2012109996A1 Aryl glycoside compound, preparation method and use thereof
08/23/2012WO2012109976A1 Use of α-mangostin in preparation of medicaments for treating alzheimer's disease
08/23/2012WO2012109752A1 Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria
08/23/2012WO2012109743A1 Methods and compositions relating to coagulation assays
08/23/2012WO2012109732A1 Compositions comprising self-assembling peptide and amino acid vehicles and active agents pp1 or pp2 and uses thereof
08/23/2012WO2012109695A1 Drug compositions for the treatment of insomnia
08/23/2012WO2012098342A8 (r)-1,2-propanediol for use as a solvent in therapeutic cooling agent compositions
08/23/2012WO2012094462A3 Heterocyclic compounds for the inhibition of pask
08/23/2012WO2012092382A3 Role of microrna in t cell immune response
08/23/2012WO2012092035A9 Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate
08/23/2012WO2012091730A3 Indole alkaloid compounds as melanogenesis promoters and uses thereof
08/23/2012WO2012091496A3 siRNA FOR INHIBITION OF Hif1α EXPRESSION AND ANTICANCER COMPOSITION CONTAINING THE SAME
08/23/2012WO2012090218A4 Synergistic effects of the combination of the specific compounds with paracetamol and their effects on various diseases
08/23/2012WO2012090177A3 Cannabinoid receptor modulators
08/23/2012WO2012089633A9 Novel pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
08/23/2012WO2012088388A9 Treating multiple myeloma
08/23/2012WO2012086964A3 Amphiphilic cyclic phosphazene trimer, hydrophobic pharmaceutical formulation micellized by amphiphilic cyclic phosphazene trimer, and preparation methods thereof
08/23/2012WO2012085249A3 Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
08/23/2012WO2012083017A3 Controlled release oral dosage forms of poorly soluble drugs and uses thereof
08/23/2012WO2012082014A3 Pharmaceutical composition for stimulating the regeneration of supporting tissues
08/23/2012WO2012081905A3 Pharmaceutical composite formulation comprising hmg-coa reductase inhibitor and aspirin
08/23/2012WO2012080727A3 Casein kinase 1delta (ck1delta) inhibitors
08/23/2012WO2012080497A3 Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
08/23/2012WO2012078121A3 Solid oral dosage form comprising cefdinir
08/23/2012WO2012077002A3 Melt processed antimicrobial composition
08/23/2012WO2012075447A3 Compositions and methods for delivering clonidine and bupivacaine to a target tissue site
08/23/2012WO2012075015A3 Oral metronidazole pharmaceutical compositions
08/23/2012WO2012074440A3 Pharmacological composition intended for intra-nasal administration with the aim of supplying a pharmacologically active component to the brain, and method for producing said composition
08/23/2012WO2012074285A3 Agent for stabilizing peptides or proteins
08/23/2012WO2012074249A3 Novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredient
08/23/2012WO2012074237A3 Liquid medicine composition including dorzolamide and brimonidine for ophthalmology
08/23/2012WO2012072692A3 Use of cytokine-releasing, biodegradable particles in hyaluronic acid for the treatment of cartilage defects, in particular of osteoarthrosis
08/23/2012WO2012069420A3 Calcium-sensing receptor-active compounds
08/23/2012WO2012062332A3 Novel photoinitiators
08/23/2012WO2012061015A3 L-citrulline supplementation during arginine depletion therapy with arginase
08/23/2012WO2012054792A3 Composition and method for immunological treatment of cancer, prevention of cancer recurrence and metastasis, and overcoming immune suppressor cells
08/23/2012WO2012025213A3 Novel therapeutic compounds
1 ... 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 ... 7860